Description:

ODM derived from http://clinicaltrials.gov/show/NCT00233662

Link:

http://clinicaltrials.gov/show/NCT00233662

Keywords:
Versions (2) ▾
  1. 2/14/12
  2. 4/13/14
Uploaded on:

April 13, 2014

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility NCT00233662 Chronic Plaque Psoriasis

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion Criteria
16 Years and older
Written informed consent
Diagnosed with chronic plaque psoriasis and require systemic therapy
CD4+ lymphocyte counts at or above the lower limit of normal for Covance Central Laboratory Services, Inc., unless on a stable dose of prednisone (counts must be at or above 300 cells/mm3).
Exclusion Criteria
Unstable erthrodermic or pustular psoriasis
Diagnosis of guttate psoriasis
Serious local infection or systemic infection within 3 months prior to first dose of alefacept
Positive for HIV antibody
Known invasive malignancy within 5 years of enrollment. Patients with a history of treated squamous cell and/or basal cell carcinomas limited to the skin are not excluded
Evidence of active tuberculosis, Current treatment for active tuberculosis or tuberculosis prophylaxis
Female patients unwilling to practice effective contraception as defined by the investigator
Female patients who are pregnant or breast-feeding
Current enrollment in any other investigational drug study
Previous participation in this study or previous alefacept studies
Medical Concepts